Heat shock proteins (HSPs) in non-alcoholic fatty liver disease (NAFLD): from molecular mechanisms to therapeutic avenues

被引:1
|
作者
Nie, Zhenwang [1 ]
Xiao, Congshu [1 ]
Wang, Yingzi [2 ]
Li, Rongkuan [1 ]
Zhao, Fangcheng [1 ]
机构
[1] Dalian Med Univ, Dept Infect Dis, Affiliated Hosp 2, Dalian, Peoples R China
[2] Dalian Med Univ, Int Med Dept, Hosp 2, Dalian, Peoples R China
基金
英国科研创新办公室;
关键词
HSP60; HSP70; HSP90; GRP78; NAFLD; Molecular mechanisms; Therapeutic strategies; ENDOPLASMIC-RETICULUM-STRESS; LIPID-ACCUMULATION; MOUSE MODEL; HEPATOCYTES; INHIBITION; EXPRESSION; PATHWAYS; CELLS;
D O I
10.1186/s40364-024-00664-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-alcoholic fatty liver disease (NAFLD), a spectrum of liver conditions characterized by fat accumulation without excessive alcohol consumption, represents a significant global health burden. The intricate molecular landscape underlying NAFLD pathogenesis involves lipid handling, inflammation, oxidative stress, and mitochondrial dysfunction, with endoplasmic reticulum (ER) stress emerging as a key contributor. ER stress triggers the unfolded protein response (UPR), impacting hepatic steatosis in NAFLD and contributing to inflammation, fibrosis, and progression to NASH and eventually hepatocellular carcinoma (HCC). Heat shock proteins (HSPs), including small HSPs such as HSP20 and HSP27, HSP60, HSP70, GRP78, and HSP90, are integral to cellular stress responses. They aid in protein folding, prevent aggregation, and facilitate degradation, thus mitigating cellular damage under stress conditions. In NAFLD, aberrant HSP expression and function contribute to disease pathogenesis. Understanding the specific roles of HSP subtypes in NAFLD offers insights into potential therapeutic interventions. This review discusses the involvement of HSPs in NAFLD pathophysiology and highlights their therapeutic potential. By elucidating the molecular mechanisms underlying HSP-mediated protection in NAFLD, this article aims to pave the way for the development of targeted therapies for this prevalent liver disorder.
引用
收藏
页数:28
相关论文
共 50 条
  • [41] From circadian clocks to non-alcoholic fatty liver disease
    Ji, Yu
    Elkin, Kenneth
    Yip, James
    Guan, Longfei
    Han, Wei
    Ding, Yuchuan
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (11) : 1107 - 1112
  • [42] The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Maciejewska-Markiewicz, Dominika
    Stachowska, Ewa
    Hawrylkowicz, Viktoria
    Stachowska, Laura
    Prowans, Piotr
    BIOMOLECULES, 2021, 11 (07)
  • [43] Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms
    Rodriguez-Calvo, Ricardo
    Samino, Sara
    Girona, Josefa
    Martinez-Micaelo, Neus
    Rafols, Pere
    Garcia-Altares, Maria
    Guaita-Esteruelas, Sandra
    Junza, Alexandra
    Heras, Mercedes
    Yanes, Oscar
    Correig, Xavier
    Masana, Lluis
    BIOMOLECULES, 2020, 10 (09) : 1 - 15
  • [44] Endotoxins and Non-Alcoholic Fatty Liver Disease
    Kessoku, Takaomi
    Kobayashi, Takashi
    Imajo, Kento
    Tanaka, Kosuke
    Yamamoto, Atsushi
    Takahashi, Kota
    Kasai, Yuki
    Ozaki, Anna
    Iwaki, Michihiro
    Nogami, Asako
    Honda, Yasushi
    Ogawa, Yuji
    Kato, Shingo
    Higurashi, Takuma
    Hosono, Kunihiro
    Yoneda, Masato
    Okamoto, Takayuki
    Usuda, Haruki
    Wada, Koichiro
    Kobayashi, Noritoshi
    Saito, Satoru
    Nakajima, Atsushi
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [45] The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
    Buzzetti, Elena
    Pinzani, Massimo
    Tsochatzis, Emmanuel A.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1038 - 1048
  • [46] Significant decrease of saturation index in erythrocytes membrane from subjects with non-alcoholic fatty liver disease (NAFLD)
    Notarnicola, Maria
    Caruso, Maria Gabriella
    Tutino, Valeria
    Bonfiglio, Caterina
    Cozzolongo, Raffaele
    Giannuzzi, Vito
    De Nunzio, Valentina
    De Leonardis, Giampiero
    Abbrescia, Daniela I.
    Franco, Isabella
    Intini, Vincenza
    Mirizzi, Antonella
    Osella, Alberto R.
    LIPIDS IN HEALTH AND DISEASE, 2017, 16
  • [47] Bioinformatics analysis reveals molecular connections between non-alcoholic fatty liver disease (NAFLD) and COVID-19
    Abolfazli, Pouria
    Aghajanzadeh, Taha
    Ghaderinasrabad, Melina
    Nchama, Cristina Nkene Apue
    Mokhlesi, Amir
    Talkhabi, Mahmood
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2022, 16 (04) : 609 - 619
  • [48] What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kosmalski, Marcin
    Frankowski, Rafal
    Ziolkowska, Sylwia
    Rozycka-Kosmalska, Monika
    Pietras, Tadeusz
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (05)
  • [49] New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
    Ali, Rafeeq
    Cusi, Kenneth
    ANNALS OF MEDICINE, 2009, 41 (04) : 265 - 278
  • [50] Agai improves non-alcoholic fatty liver disease (NAFLD) induced by fructose
    de Freitas Carvalho, Mayara Medeiros
    Teixeira Reis, Larissa Lelis
    Macedo Lopes, Juliana Marcia
    Lage, Nara Nunes
    da Costa Guerra, Joyce Ferreira
    Zago, Helena Porto
    Bonomo, Larissa de Freitas
    Pereira, Renata Rebeca
    de Lima, Wanderson Geraldo
    Silva, Marcelo Eustaquio
    Pedrosa, Maria Lucia
    NUTRICION HOSPITALARIA, 2018, 35 (02) : 318 - 325